Engineered nanoparticle tech helps stop internal bleeding

Internal bleeding is a serious medical emergency. It may be caused by numerous medical conditions such as traumas or chronic diseases and it occurs in various body parts including the brain or the stomach. Yet the prognosis for majority of cases is quite pessimistic, as internal bleeding usually causes hematomas, organ dysfunction and massive blood loss.

Although there are several drugs that can stop severe blood loss, none of them can help entirely without surgical intervention. In an attempt to stop bleeding more effectively, scientists are developing drugs that can be applied using a simple injection.

The main issue with such drugs is that the remedy has to initiate clot formation only at the site of vessel damage instead of affecting the entire vascular system.

In a new study, scientists from ITMO University suggested using magnet-driven nanoparticles to solve this problem. The particles consist of two key components. The first is thrombin, an enzyme responsible for blood clotting.

It interacts with the protein called fibrinogen and triggers clot formation in order to block the damaged vessel. The thrombin is wrapped into a special porous matrix made of magnetite. This mineral is the second main ingredient and allows for precise control of the movement of particles inside the body using an external magnetic field.

Magnetic nanoparticles with thrombin have low activity and do not cause blood clotting if they are evenly distributed in blood vessels. Therefore it is possible to inject a solution of particles intravenously and localise them where needed using a magnet.

When the patient receives an extra portion of fibrinogen, thrombin particles around the site of injury interact with it and the bleeding stops faster.

"We tested the nanoparticles’ efficiency on human blood plasma samples and a special vessel model,” says Andrey Drozdov, member of SCAMT Laboratory at ITMO University. “After the first experiments with plasma, we found out that thrombin in our nanoparticles is less active compared to its free variant.

Yet we went on with the tests and ran additional experiments on a model of the blood stream. We were able to observe how nanoparticles behave when the vessel is damaged. It turned out that magnetic localisation compensates for lower activity. Nanoparticles reduce the clotting time by 6.5 times and can reduce total blood loss by 15 times.”

"Synthesising these nanoparticles is not easy,” says head of the laboratory Vladimir Vinogradov. “It is important to keep their size down to 200 nanometers; otherwise they will not be suitable for injection".

"In addition, mild synthesis conditions are required so that the thrombin molecule does not break down and lose its activity completely. Finally, we could only use biocompatible components. We checked the toxicity of our particles with human cells and made sure they are completely safe even during prolonged exposure.”

Discover more here.

Image credit: ITMO University.